"Many European medtech companies fail to approach patent portfolio development strategically, often spending more money than necessary without adequate protection or losing investors during due diligence."
"As European companies look to expand in the U.S. market, understanding U.S. patent law intricacies becomes crucial. European-centric strategies often misalign with U.S. expectations."
Collection
[
|
...
]